Gyre Therapeutics announced on June 10, 2025, that the first volunteer has been dosed in a Phase 1 clinical trial evaluating F230 for the treatment of pulmonary arterial hypertension (PAH) in China. This milestone marks the company's entry into the PAH field.
F230 is a novel endothelin A (ETA) receptor antagonist designed to reduce pulmonary vascular remodeling and lower pulmonary pressure. The Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of F230 in healthy volunteers.
PAH is a rare, progressive, and high-mortality cardiovascular condition, with China's PAH market valued at $370 million in 2023 and projected to grow to $480 million by 2031. This pipeline expansion leverages Gyre's clinical development platform and commercial infrastructure in China.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.